Priority List Immunomolecular Therapeutics

EAY191-S3

II

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Patients with AKT-Altered Advanced Non-Breast Solid Tumors

CTSU/AHOD2131

III

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

CTSU/A151804

Other

ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS